The physiology and pharmacology research puogression of T-ceu potassium channel

Abstract

Abstract: The voltage-gated Kv1.3 channel and the Ca²⁺-activated IKCa1 K⁺ channel are expressed in T cells in a distinct pattern that depends on the state of lymphocyte activation and differentiation. The channel phenotype changes during the progression from the resting to the activated cell state and from naïve to effector memory cells. Kv1.3 and IKCa1 channel are related to the activation of T lymphocyte, and the specific K⁺ channel blockers can be used in the therapy of many diseases such as autoimmune diseases. In this article, we review the functional roles of these channels in both naïve cells and memory cells, describe the development of selective inhibitors of Kv1.3 and IKCa1 channels, and provide a rationale for the potential therapeutic use of these inhibitors in immunological disorders.

Key words: T lymphocyte, K⁺ channel, Inhibitors of K⁺ channel

CLC Number:

R331

QIU Hong-xia, ZHAO Yin-huan, ZHU Gui-qi, ZHAO Hai-hui. The physiology and pharmacology research puogression of T-ceu potassium channel[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 352-356.

References

[1] Mello de Queiroz F, Ponte CG, Bonomo A, et al. Study of membrane potential in T lymphocytes subpopulations using flow cytometry[J].BMC Immunology,2008,9(63):1471-2172.
[2] Nicolaou SA, Neumeier L, Steckly A, et al. Localization of Kv1.3 channels in the immunological synapse modulates the calcium response to antigen stimulation in T lymphocytes [J]. Immunol, 2009, 183(10):6296-6302.
[3] Chandy KG, Wulff H, Beeton C, et al. K⁺ channels as targets for specific immunomodulation [J].Trends Pharmacol Sci, 2004, 25(5):280-289.
[4] 郑付春,贾强用,石刚刚.Ca²⁺/PKC通路在大鼠缺氧复氧心肌细胞Egr-1高表达中的作用[J]. 中国临床药理学与治疗学, 2011,V16(3): 241-248.
[5] Nicolaou SA, Neumeier L, Takimoto K, et al. Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus[J].Cell Calcium,2010,47(1):19-28.
[6] Panyi G, Possani LD, Rodríguez de la Vega RC, et al. K⁺ channel blockers: Novel tools to inhibit T cell activation leading to specific immunosuppression[J]. Curr Pharm Des, 2006,12(18):2199-2220.
[7] Dauplais M,Lecoq A,Song J,et al. On the convergent evolution of animal toxins.Conservation of a diad of functional residues in potassium channel-blocking toxins with unrelated structures[J]. Biochemistry, 1997, 72(7):4302-4309.
[8] Beeton C, Smith BJ, Sabo JK, et al. The D-Diastereomer of ShK Toxin Selectively Bolcks Voltage-gated K⁺ Channels and Inhibits T Lymphocyte Proliferation[J]. J Biol Chem, 2008,283(2):988-997.
[9] Pennington MW, Beeton C, Galea CA, et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes[J]. Mol Pharmacol, 2009, 75(4):762-773.
[10] Han S, Yi H, Yin SJ, et al. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease [J]. J Biol Chem, 2008, 283(27):19058-19065.
[11] Mix E,Goertsches R,Zettl UK. Immunology and neurology[J]. Neurology, 2007, 254(Suppl 2):112-117.
[12] Schmitz A, Sankaranarayanan A, Azam P, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases[J].Mol Pharmacol,2005,68(5):1254-1270.
[13] Azam P, Sankaranarayanan A, Homerick D, et al. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis[J]. J Invest Dermatol, 2007,127(6):1419-1429.
[14] Ahn HS, Kim SE, Choi BH, et al. Calcineurin- independent inhibition of Kv1.3 by FK-506(tacrolimus):a novel pharmacological property[J].Am J Physiol Cell Physiol, 2007, 292(5):C 1714-C1722.
[15] Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders [J]. Curr Opin Drug Discov Dev, 2003,6(5): 640-647.
[16] Wulff H, Miller MJ, Hansel W, et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca²⁺ -activated K⁺ channel, IKCa1: A potential immunosuppressant[J].Proc Natl Acad Sci USA, 2000, 97(14):8151-8156.
[17] Wulff H, Gutman GA, Cahalan MD, et al. Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel IKCa1 [J]. Biol Chem, 2001,276(34): 32040-32045.
[18] Kohler R, Wulff H, Eichler I, et al. Blockade of the intermediate- conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis[J].Circulation, 2003,108(9):1119-1125.
[19] Urbahns K, Horvath E, Stasch JP, et al. 4-Phenyl-4H-pyrans as IKCa channel blockers. [J].Bioorg Med Chem Lett, 2003,13(16):2637-2639.
[20] Grgic I,Wulff H,Eichler I, et al. Blockade of T-Lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection[J]. Transplant Proc,2009,41(6):2601-2606.
[21] Beeton C, Wulff H, Barbaria J, et al. Selective blockade of T lymphocyte K⁺ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis[J]. Proc Natl Acad Sci USA, 2001,98(24): 13942-13947.
[22] Rus H, Pardo CA, Hu L, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain[J].Proc Natl Acad Sci,2005,102(31):11094-11099.
[23] 胡晓静.T细胞电压门控钾通道Kv1.3在再生障碍性贫血中的作用研究[D].内科学(血液病),2009
[24] Beeton C, Pennington MW, Wulff H, et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases[J]. Mol Pharmacol, 2005, 67(4): 1369-1381.
[25] Schmitz A, Sankaranarayanan A, Azam P, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases[J]. Mol Pharmacol, 2005, 68(5): 1254-1270.
[26] Beeton C, Wulff H, Standifer NE, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases[J]. PNAS, 2006, 103(46): 17414-17419.
[27] Gilhar A, Bergman R, Assay B, et al. The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model[J]. J Invest Dermatol, 2011,131(1):118-124.
[28] Matheu MP, Beeton C, Garcia A, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block[J].Immunity,2008, 29(4) 602-614.